Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Rheumatology (2013)
- Fellowship: Stanford University Immunology and Rheumatology Fellowship (1998) CA
- Residency: Stanford University Internal Medicine Residency (1996) CA
- Residency: Stanford University Internal Medicine Residency (1995) CA
- Internship: Stanford University Internal Medicine Residency (1993) CA
- Medical Education: Johns Hopkins University School of Medicine (1992) MD
Publications
-
A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus
van Vollenhoven, R. F., Park, J. L., Genovese, M. C., West, J. P., & McGuire, J. L. (1999). A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. LUPUS, 8(3), 181–187. -
-
A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.
Pan, J., Kunkel, E. J., Gosslar, U., Lazarus, N., Langdon, P., Broadwell, K., … Soler, D. (2000). A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. Journal of Immunology , 165(6), 2943–49. -
-
Current management of rheumatoid arthritis
Genovese, M. C., & Davis, J. S. (2001). Current management of rheumatoid arthritis. HOSPITAL PRACTICE, 36(2), 21-? -
Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential
Kim, C. H., Kunkel, E. J., Boisvert, J., Johnston, B., Campbell, J. J., Genovese, M. C., … BUTCHER, E. C. (2001). Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. JOURNAL OF CLINICAL INVESTIGATION, 107(5), 595–601. -
Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival
Uhrin, Z., Wang, B. W. E., Matsuda, Y., Strober, S., & Genovese, M. C. (2001). Treatment of rheumatoid arthritis with total lymphoid irradiation - Long-term survival. ARTHRITIS AND RHEUMATISM, 44(7), 1525–28. -
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
Robinson, W. H., Genovese, M. C., & Moreland, L. W. (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? ARTHRITIS AND RHEUMATISM, 44(9), 1977–1983. -
-
-
Autoantigen microarrays for multiplex characterization of autoantibody responses
Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., KAMACHI, M., Dean, E. J., … Utz, P. J. (2002). Autoantigen microarrays for multiplex characterization of autoantibody responses. NATURE MEDICINE, 8(3), 295–301. -
-
Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes
Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., … Finck, B. K. (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes. ARTHRITIS AND RHEUMATISM, 46(6), 1443–1450. -
Central nervous system lupus and pregnancy: 11-year experience at a single center.
El-Sayed, Y. Y., Lu, E. J., Genovese, M. C., Lambert, R. E., Chitkara, U., & Druzin, M. L. (2002). Central nervous system lupus and pregnancy: 11-year experience at a single center. Journal of Maternal-Fetal & Neonatal Medicine , 12(2), 99–103. -
-
Rheumatic syndromes associated with malignancy
Chakravarty, E., & Genovese, M. C. (2003). Rheumatic syndromes associated with malignancy. CURRENT OPINION IN RHEUMATOLOGY, 15(1), 35–43. -
-
Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles.
Goodman, S., Trindade, M., Ma, T., Lee, M., Wang, N., Ikenou, T., … Smith, R. L. (2003). Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. Journal of Biomedical Materials Research. Part A, 65(1), 43–50. -
Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging
Yoshioka, H., Alley, M., Steines, D., Stevens, K., Rubesova, E., Genovese, M., … Lang, P. (2003). Imaging of the articular cartilage in osteoarthritis of the knee joint: 3D spatial-spectral spoiled gradient-echo vs. fat-suppressed 3D spoiled gradient-echo MR imaging. JOURNAL OF MAGNETIC RESONANCE IMAGING, 18(1), 66–71. -
COX-2 selective inhibitors and bone
Goodman, S. B., Ma, T., Genovese, M., & Smith, R. L. (2003). COX-2 selective inhibitors and bone. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 16(3), 201–205. -
-
A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626].
Genovese, M. C., Chakravarty, E. F., Krishnan, E., & Moreland, L. W. (2004). A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Research & Therapy, 6(1), R73–R77. -
-
Articular cartilage of knee: Normal patterns at MR imaging that mimic disease in healthy subjects and patients with osteoarthritis
Yoshioka, H., Stevens, K., Genovese, M., Dillingham, M. F., & Lang, P. (2004). Articular cartilage of knee: Normal patterns at MR imaging that mimic disease in healthy subjects and patients with osteoarthritis. RADIOLOGY, 231(1), 31–38. -
-
Associations between rheumatoid arthritis and malignancy
Chakravarty, E. F., & Genovese, M. C. (2004). Associations between rheumatoid arthritis and malignancy. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 271-? -
Treatment of rheumatoid arthritis with etanercept
Genovese, M. C., & Kremer, J. M. (2004). Treatment of rheumatoid arthritis with etanercept. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 30(2), 311-? -
-
-
Temporal effects of a COX-2-selective NSAID on bone ingrowth.
Goodman, S. B., Ma, T., Mitsunaga, L., Miyanishi, K., Genovese, M. C., & Smith, R. L. (2005). Temporal effects of a COX-2-selective NSAID on bone ingrowth. Journal of Biomedical Materials Research. Part A, 72(3), 279–87. -
Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus
Chakravarty, E. F., Colon, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., Genovese, M. C., & Druzin, M. L. (2005). Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 192(6), 1897–1904. -
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
Genovese, M. C., Bathon, J. M., Fleischmann, R. M., Moreland, L. W., Martin, R. W., Whitmore, J. B., … Leff, J. A. (2005). Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. JOURNAL OF RHEUMATOLOGY, 32(7), 1232–1242. -
Antigen microarray profiling of autoantibodies in rheumatoid arthritis
Hueber, W., Kidd, B. A., Tomooka, B. H., Lee, B. J., Bruce, B., Fries, J. F., … Robinson, W. H. (2005). Antigen microarray profiling of autoantibodies in rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 52(9), 2645–2655. -
-
-
A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis
Genovese, M. C., Chakravarty, E. F., Boyle, D. L., Tutuncu, Z., Thorburn, C. M., Halilhodzic, M., … Kavanaugh, A. (2005). A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. JOURNAL OF RHEUMATOLOGY, 32(12), 2345–50. -
Biologic therapies in clinical development for the treatment of rheumatoid arthritis
Genovese, M. C. (2005). Biologic therapies in clinical development for the treatment of rheumatoid arthritis. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 11(3), S45–S54. -
-
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., Higgins, J. P., … Robinson, W. H. (2006). Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. JOURNAL OF CLINICAL INVESTIGATION, 116(10), 2633–42. -
-
A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands
Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., Hillygus, J., & Genovese, M. C. (2007). A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. JOURNAL OF RHEUMATOLOGY, 34(6), 1323–27. -
-
-
Efficacy results from pivotal clinical trials with abatacept
Rozelle, A. L., & Genovese, M. C. (2007). Efficacy results from pivotal clinical trials with abatacept. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25(5), S30–S34. -
-
-
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., … Gomez-Rein, J. J. (2008). Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study. ARTHRITIS AND RHEUMATISM, 58(10), 2968–80. -
-
Inhibition of p38: Has the Fat Lady Sung
Genovese, M. C. (2009). Inhibition of p38: Has the Fat Lady Sung. ARTHRITIS AND RHEUMATISM, 60(2), 317–320. -
Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
Emery, P., Genovese, M. C., van Vollenhoven, R., Sharp, J. T., Patra, K., & Sasso, E. H. (2009). Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 36(7), 1429–1441. -
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
Hueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., Tibshirani, R. J., … Robinson, W. H. (2009). Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. ARTHRITIS RESEARCH & THERAPY, 11(3). -
First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy
Schmajuk, G., & Genovese, M. C. (2009). First Report of Idiopathic Granulomatous Mastitis Treated with Methotrexate Monotherapy. JOURNAL OF RHEUMATOLOGY, 36(7), 1559–1560. -
LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
Genovese, M. C., Van den Bosch, F., ROBERSON, S. A., Bojin, S., Biagini, I. M., Ryan, P., & Sloan-Lancaster, J. (2010). LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study. ARTHRITIS AND RHEUMATISM, 62(4), 929–39. -
Abatacept in the Treatment of Patients With Psoriatic Arthritis
Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., … Gladman, D. (2011). Abatacept in the Treatment of Patients With Psoriatic Arthritis. ARTHRITIS AND RHEUMATISM, 63(4), 939–948. -
-
-
Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial
Genovese, M. C., Kinnman, N., de La Bourdonnaye, G., Rossi, C. P., & Tak, P. P. (2011). Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Antagonist Therapy Results of a Phase II, Randomized, Placebo-Controlled, Dose-Finding Trial. ARTHRITIS AND RHEUMATISM, 63(7), 1793–1803. -
Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
Genovese, M. C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., Valente, R., … Alten, R. (2011). Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate. ARTHRITIS AND RHEUMATISM, 63(10), 2854–64. -
-
-
-
Effects of sclerostin antibody on healing of a non-critical size femoral bone defect
Jawad, M. U., Fritton, K. E., Ma, T., Ren, P.-G., Goodman, S. B., Ke, H. Z., … Genovese, M. C. (2013). Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. JOURNAL OF ORTHOPAEDIC RESEARCH, 31(1), 155–63. -
-
-
Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial
Genovese, M. C., Bojin, S., Biagini, I. M., Mociran, E., Cristei, D., Mirea, G., … Sloan-Lancaster, J. (2013). Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial. ARTHRITIS AND RHEUMATISM, 65(4), 880–889. -
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Jones, D. A., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2013). Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. JOURNAL OF RHEUMATOLOGY, 40(4), 369–378. -
-
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Stohl, W., Merrill, J. T., McKay, J. D., Lisse, J. R., Zhong, Z. J., Freimuth, W. W., & Genovese, M. C. (2013). Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. JOURNAL OF RHEUMATOLOGY, 40(5), 579–589. -
-
Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension
Keystone, E. C., Genovese, M. C., Hall, S., Miranda, P. C., Bae, S.-C., Palmer, W., … Hsia, E. C. (2013). Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension. JOURNAL OF RHEUMATOLOGY, 40(7), 1097–1103. -
Lemierre's syndrome
Lee, B. K., LOPEZ, F., Genovese, M., & Loutit, J. S. (1997). Lemierre's syndrome. SOUTHERN MEDICAL JOURNAL, 90(6), 640–43. -
Fever, rash, and arthritis in a woman with silicone gel breast implants
Genovese, M. C. (1997). Fever, rash, and arthritis in a woman with silicone gel breast implants. WESTERN JOURNAL OF MEDICINE, 167(3), 149–158. -
Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment
Genovese, M. C. (1998). Joint and soft-tissue injection - A useful adjuvant to systemic and local treatment. POSTGRADUATE MEDICINE, 103(2), 125-? -
Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab
Breedveld, F. C., Khraishi, M. M., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., … Cooper, S. (2007). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. JOURNAL OF RHEUMATOLOGY, 34(7), 1602–1602. -
Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab
Breedveld, F. C., Van Vollenhoven, R. F., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., … Cooper, S. (2006). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. TAYLOR & FRANCIS AS. -
Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab
Breedveld, F. C., Genovese, M., Emery, P., Moreland, L. W., Keystone, E., Matteson, E. L., … Cooper, S. (2006). Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. Presented at the Annual European Congress of Rheumatology (EULAR 2006), AMSTERDAM,NETHERLANDS: BMJ PUBLISHING GROUP. -
-
A randomized, blinded, parallel group, placebo-controlled, pilot study evaluating the effect of Pvac treatment in patients with diffuse systemic sclerosis
Genovese, M. C., Boyle, D., Chakravarty, E., Tutuncu, Z., Thorburn, C., Halilhodzic, M., … Kavanaugh, A. (2004). A randomized, blinded, parallel group, placebo-controlled, pilot study evaluating the effect of Pvac treatment in patients with diffuse systemic sclerosis. ARTHRITIS AND RHEUMATISM, 50(9), S636–S636. -
24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
Genovese, M. C., Keystone, E., Taylor, P., Drescher, E., Berclaz, P.-Y., Lee, C. H., … Macias, W. (2012). 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S1049–S1050. -
Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
Peterfy, C. G., Emery, P., Genovese, M. C., Keystone, E., Taylor, P., Berclaz, P.-Y., … Macias, W. (2012). Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S1050–S1051. -
12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Smolen, J. S., Schlichting, D. E., Sterling, K. L., Keystone, E., Taylor, P., Genovese, M. C., … Gaich, C. L. (2012). 12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 64(10), S214–S214. -
24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Taylor, P., Genovese, M., Keystone, E. C., Drescher, E., Berclaz, P.-Y., Lee, C., … Macias, W. (2013). 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Presented at the Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology, BIRMINGHAM,ENGLAND,ENGLAND,ENGLAND: OXFORD UNIV PRESS. -
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
Schiff, M., Pritchard, C., Huffstutter, J. E., Rodriguez-Valverde, V., Durez, P., Zhou, X., … Genovese, M. C. (2009). The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. ANNALS OF THE RHEUMATIC DISEASES, 68(11), 1708–1714. -
Synovial proteome microarrays identify deiminated proteins as targets of the autoantibody response in Rheumatoid Arthritis
Hueber, W., Lee, B. J., Genovese, M. C., Bruce, B., van Venrooij, W. J., Smolen, J. S., … Robinson, W. H. (2003). Synovial proteome microarrays identify deiminated proteins as targets of the autoantibody response in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, 48(9), S429–S429. -
Multiplex autoantibody profiling using 'synovial proteome' microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis
Hueber, W., Lee, B. J., Genovese, M., van Venrooij, W., Steinman, L., Utz, P. J., & Robinson, W. H. (2003). Multiplex autoantibody profiling using 'synovial proteome' microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis. Presented at the 3rd World Congress of the Global-Arthritis-Research-Network (GARN), Miyakazi,JAPAN: BIOMED CENTRAL LTD. -
Arthritis antigen microarray analysis reveals associations of distinct autoantibody profiles with markers of disease activity and severity in RA.
Hueber, W., Kidd, B., Lee, B. J., Genovese, M., Bruce, B., Fries, J., … Robinson, W. H. (2004). Arthritis antigen microarray analysis reveals associations of distinct autoantibody profiles with markers of disease activity and severity in RA. ARTHRITIS AND RHEUMATISM, 50(9), S651–S651. -
-
Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex)
Emery, P., Keystone, E., Peterfy, C. G., Tak, P.-P., Cohen, S. B., Genovese, M. C., … Shaw, T. M. (2008). Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (reflex). Presented at the Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology, LIVERPOOL,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND,ENGLAND: OXFORD UNIV PRESS. -
-
The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIN trial.
Genovese, M., Luggen, M., Kremer, J., Sany, J., Aranda, R., Becker, J. C., … Dougados, M. (2005). The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIN trial. ARTHRITIS AND RHEUMATISM, 52(9), S137–S137. -
Selective co-stimulation modulation with abatacept leads to improvements in ACR responses in patients with an inadequate response to etanercept, infliximab or both: The ATTAIN trial.
Dougados, M., Kavanagh, A., Espinoza, L., Sibilia, J., Aranda, R., Becker, J. C., … Luggen, M. (2005). Selective co-stimulation modulation with abatacept leads to improvements in ACR responses in patients with an inadequate response to etanercept, infliximab or both: The ATTAIN trial. ARTHRITIS AND RHEUMATISM, 52(9), S137–S138. -
Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial
Dougados, M., Schiff, M., Luggen, M., Becker, J. C., Aranda, R., Li, T., … Genovese, M. C. (2007). Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial. Presented at the Annual Meeting of the British-Society-of-Rheumatology, BIRMINGHAM,ENGLAND,ENGLAND: OXFORD UNIV PRESS. -
SAFETY, EFFICACY AND HEALTH-RELATED QUALITY OF LIFE THROUGH 5 YEARS OF ABATACEPT TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO ANTI-TUMOUR NECROSIS FACTOR THERAPY
Genovese, M. C., Schiff, M., Luggen, M., Le Bars, M., Becker, J.-C., Aranda, R., … DougadoS, M. (2011). SAFETY, EFFICACY AND HEALTH-RELATED QUALITY OF LIFE THROUGH 5 YEARS OF ABATACEPT TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO ANTI-TUMOUR NECROSIS FACTOR THERAPY. Presented at the Annual Meeting of the British-Society-for-Rheumatology 2011, BRIGHTON,ENGLAND: OXFORD UNIV PRESS. -
CTLA4IG (BMS-188667) in a phase IIB, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers
Schiff, M., Genovese, M., Nuamah, I., Becker, J., & Weinblatt, M. (2003). CTLA4IG (BMS-188667) in a phase IIB, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving etanercept: Association between clinical response and key biomarkers. Presented at the Annual European Congress of Rheumatology, LISBON,PORTUGAL: BMJ PUBLISHING GROUP. -
Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial.
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., McCann, T., … Dougados, M. (2006). Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. ARTHRITIS AND RHEUMATISM, 54(9), S244–S244. -
Efficacy and safety of abatacept (CTLA41g), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-alpha therapy: Results of the phase III ATTAIN (Abatacept trial in treatment of Anti-TNF INadequate responders)
Genovese, M., Luggen, M., Schiff, M., Sherrer, Y., Nuamah, I., Aranda, R., … Dougados, M. (2004). Efficacy and safety of abatacept (CTLA41g), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-alpha therapy: Results of the phase III ATTAIN (Abatacept trial in treatment of Anti-TNF INadequate responders). ARTHRITIS AND RHEUMATISM, 50(12), 4103–4103. -
Efficacy of abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate Responders) trial: Current versus prior discontinuation.
Genovese, M., Schiff, M., Luggen, M., Aranda, R., Becker, J. C., White, A., & Dougados, M. (2005). Efficacy of abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate Responders) trial: Current versus prior discontinuation. ARTHRITIS AND RHEUMATISM, 52(9), S560–S561. -
Beneficial effects of the selective CO-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment
Emery, R., Westhovens, R., LEON, G., Nuamah, I., Ge, Z., Aranda, R., … Dougados, M. (2005). Beneficial effects of the selective CO-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment. Presented at the Annual European Congress of Rheumatology, VIENNA,AUSTRIA: BMJ PUBLISHING GROUP. -
Abatacept leads to significant improvements in all American college of rheumatology core components in patients with an inadequate response to anti-TNF therapy in the attain trial
Schiff, M., Dougados, M., Luggen, M., Espinoza, L., Nuamah, I., Aranda, R., … Genovese, M. (2005). Abatacept leads to significant improvements in all American college of rheumatology core components in patients with an inadequate response to anti-TNF therapy in the attain trial. Presented at the Annual European Congress of Rheumatology, VIENNA,AUSTRIA: BMJ PUBLISHING GROUP. -
Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data.
Genovese, M. C., Hochberg, M. C., Cohen, R. B., Weinblatt, M. E., Kaine, J., Keystone, E., … Alten, R. (2012). Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data. ARTHRITIS AND RHEUMATISM, 64(10), S725–S725. -
Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to MethotrexatE) Trial.
Genovese, M. C., Covarrubias Cobos, A., Leon, G., Mysler, E. F., Keiserman, M. W., Valente, R. M., … Alten, R. (2011). Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to MethotrexatE) Trial. ARTHRITIS AND RHEUMATISM, 63(10), S150–S150. -
-
Safety Profile of Subcutaneous Abatacept Focusing on Clinically Relevant Events in Patients with Rheumatoid Arthritis (RA) and up to 4.5 Years of Exposure.
Alten, R., Kaine, J. L., Keystone, E., Nash, P. T., Delaet, I., Qi, K., & Genovese, M. C. (2011). Safety Profile of Subcutaneous Abatacept Focusing on Clinically Relevant Events in Patients with Rheumatoid Arthritis (RA) and up to 4.5 Years of Exposure. ARTHRITIS AND RHEUMATISM, 63(10), S150–S151. -
Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
Genovese, M. C., Pacheco-Tena, C., Covarrubias, A., LEON, G., Mysler, E., Keiserman, M., … Alten, R. (2012). Subcutaneous Abatacept: Long-Term Data From the Acquire Trial. ARTHRITIS AND RHEUMATISM, 64(10), S201–S201. -
THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) IS CONSISTENT WITH THE ESTABLISHED INTRAVENOUS (IV) PROFILE IN A STUDY OF 1457 PATIENTS WITH RA AND AN INADEQUATE RESPONSE TO MTX (MTX-IR)
Nash, P., Genovese, M., COVARRUBIAS, J., LEON, G., Mysler, E., Keiserman, M., … Bamford, T. (2011). THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) IS CONSISTENT WITH THE ESTABLISHED INTRAVENOUS (IV) PROFILE IN A STUDY OF 1457 PATIENTS WITH RA AND AN INADEQUATE RESPONSE TO MTX (MTX-IR). WILEY-BLACKWELL. -
THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) WITH OR WITHOUT MTX IN PATIENTS WITH ACTIVE RA
Nash, P., Nayiager, S., Genovese, M., Rodriguez, C., Delaet, I., Elegbe, A., … Bamford, T. (2011). THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) WITH OR WITHOUT MTX IN PATIENTS WITH ACTIVE RA. WILEY-BLACKWELL. -
SAFETY PROFILE OF SUBCUTANEOUS ABATACEPT FOCUSING ON CLINICALLY RELEVANT EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND UP TO 4.5 YEARS OF EXPOSURE
Alten, R., Kaine, J. L., Keystone, E., Nash, P. T., Delaet, I., Qi, K., & Genovese, M. C. (2012). SAFETY PROFILE OF SUBCUTANEOUS ABATACEPT FOCUSING ON CLINICALLY RELEVANT EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND UP TO 4.5 YEARS OF EXPOSURE. Presented at the Annual Meeting of the British-Society-for-Rheumatology, GLASGOW,SCOTLAND: OXFORD UNIV PRESS. -
-
-
IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study
Genovese, M., McKay, J., Nasonov, E., Myster, E., da Silva, N., Alecock, E., … Gomez-Reino, J. (2007). IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study. ARTHRITIS AND RHEUMATISM, 56(12), 4309–4310. -
RAPID AND SIGNIFICANT REDUCTION OF DAS28 FOLLOWING TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Smolen, J. S., Mysler, E. F., Rubbert-Roth, A., Gomez-Reino, J., Alten, R., Law, A., … Genovese, M. (2009). RAPID AND SIGNIFICANT REDUCTION OF DAS28 FOLLOWING TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. Presented at the Annual Meeting of the British-Society-of-Rheumatology, GLASGOW,SCOTLAND: OXFORD UNIV PRESS. -
RAPID AND SIGNIFICANT REDUCTION IN DISEASE ACTIVITY WITH TOCILIZUMAB IN COMBINATION WITH SIX DIFFERENT DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: THE TOWARD STUDY
Gomez-Reino, J. J., Nasonov, E. L., McKay, J. D., Mysler, E. F., da Silva, N., Alecock, E., … Genovese, M. C. (2009). RAPID AND SIGNIFICANT REDUCTION IN DISEASE ACTIVITY WITH TOCILIZUMAB IN COMBINATION WITH SIX DIFFERENT DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: THE TOWARD STUDY. Presented at the Annual Meeting of the British-Society-of-Rheumatology, GLASGOW,SCOTLAND: OXFORD UNIV PRESS. -
Quality of life and functional improvements with the IL-6 receptor inhibitor tocilizumab in patients with active rheumatoid arthritis despite DMARD therapy: The toward study
Gomez-Reino, J. J., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., Laughton, J., … Genovese, M. C. (2008). Quality of life and functional improvements with the IL-6 receptor inhibitor tocilizumab in patients with active rheumatoid arthritis despite DMARD therapy: The toward study. Presented at the Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology, LIVERPOOL,ENGLAND: OXFORD UNIV PRESS. -
IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study
Genovese, M., Brown, J. P., McKay, J., Nasonov, E., Mysler, E., da Silva, N., … Gomez-Reino, J. (2008). IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study. JOURNAL OF RHEUMATOLOGY. MT TREMBLANT,CANADA,CANADA: J RHEUMATOL PUBL CO. -
Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs
Gomez-Reino, J. J., Nair, B., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., & Genovese, M. (2008). Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs. JOURNAL OF RHEUMATOLOGY, 35(6), 1216–1216. -
Targeted inhibition of IL-6 signalling withtocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs
Gomez-Reino, J. J., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., & Genovese, M. (2007). Targeted inhibition of IL-6 signalling withtocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs. ARTHRITIS AND RHEUMATISM, 56(12), 4234–4234. -
Combination therapy of leflunomide (LEF) & methotrexate (MTX) is effective & well tolerated in RA patients inadequately responding to MTX alone
Kremer, J. M., Genovese, M., Cannon, G. W., Caldwell, J. R., Cush, J. J., & Bathon, J. (2001). Combination therapy of leflunomide (LEF) & methotrexate (MTX) is effective & well tolerated in RA patients inadequately responding to MTX alone. J RHEUMATOL PUBL CO. -
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2010). An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. NEW ENGLAND JOURNAL OF MEDICINE, 363(14), 1303–1312. -
-
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial
Kremer, J., Genovese, M., Cannon, G. W., Caldwell, J., Cush, J., Furst, D. E., … Strand, V. (2004). Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial. JOURNAL OF RHEUMATOLOGY, 31(8), 1521–1531. -
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate - A randomized, double-blind, placebo-controlled trial
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E., … Bathon, J. M. (2002). Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate - A randomized, double-blind, placebo-controlled trial. ANNALS OF INTERNAL MEDICINE, 137(9), 726–733. -
Running and osteoarthritis of the knee: A 12 year longitudinal study.
Lane, N. E., Oehlert, J., Ward, M., Genovese, M., Bloch, D., & Fries, J. F. (1997). Running and osteoarthritis of the knee: A 12 year longitudinal study. ARTHRITIS AND RHEUMATISM, 40(9), 1242–1242. -
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
Robinson, W. H., Paniagua, R. T., Ho, P. P., Chan, S. M., Sharpe, O., Utz, P. J., & Genovese, M. C. (2006). Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. ARTHRITIS AND RHEUMATISM, 54(9), S356–S357. -
A pilot study of TNF inhibition in Erosive/Inflammatory osteoarthritis of the hands.
Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., Hillygus, J. J., & Genovese, M. C. (2006). A pilot study of TNF inhibition in Erosive/Inflammatory osteoarthritis of the hands. ARTHRITIS AND RHEUMATISM, 54(9), S674–S674. -
-
-
Safety of TNF inhibitors (TNF-is) and non-biologic DMARDs in rheumatoid arthritis (RA) patients (pts) previously treated with Rituximab (RTX)
Genovese, M., van Vollenhoven, R., Breedveld, F., Emery, P., Moreland, L., Keystone, E., … Shaw, T. (2008). Safety of TNF inhibitors (TNF-is) and non-biologic DMARDs in rheumatoid arthritis (RA) patients (pts) previously treated with Rituximab (RTX). INFORMA HEALTHCARE. -
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
Hansen, K. E., Cush, J. J., Patel, S., Genovese, M. C., & Schiff, M. (2002). The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. ARTHRITIS AND RHEUMATISM, 46(9), S538–S538. -
Golimumab administered subcutaneously every 4 wks in patients with active rheumatoid arthritis despite methotrexate: Wk 24 results of the randomized, double-blind, placebo-controlled, GO-FORWARD study
Keystone, E., Genovese, M. C., Klareskog, L., Hsia, E. C., Livingston, J., Wiekowski, M., … Rahman, M. U. (2008). Golimumab administered subcutaneously every 4 wks in patients with active rheumatoid arthritis despite methotrexate: Wk 24 results of the randomized, double-blind, placebo-controlled, GO-FORWARD study. ARTHRITIS AND RHEUMATISM, 58(9), S618–S619. -
-
-
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
Keystone, E., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S., Miranda, P. C., … Rahman, M. U. (2010). Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. ANNALS OF THE RHEUMATIC DISEASES, 69(6), 1129–1135. -
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., … Finck, B. K. (2000). A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. NEW ENGLAND JOURNAL OF MEDICINE, 343(22), 1586–1593. -
-
Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.
Wasko, M. C., Hsia, E. C., Kirkham, B., Touboul, P.-J., Fleischmann, R., Genovese, M. C., … Rahman, M. U. (2014). Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides. Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases, 20(1), 1–10. -
Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation
Kirkham, B. W., Wasko, M. C., Hsia, E. C., Fleischmann, R. M., Genovese, M. C., Matteson, E. L., … Rahman, M. U. (2014). Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation. ANNALS OF THE RHEUMATIC DISEASES, 73(1), 161–169. -
-
Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial.
Genovese, M. C., Tena, C. P., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., … Alten, R. (2014). Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial. Journal of Rheumatology, 41(4), 629–39. -
-
-
-
The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy
Emery, P., Fleischmann, R., van der Heijde, D., Keystone, E. C., Genovese, M. C., Conaghan, P. G., … Rahman, M. U. (2011). The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy. ARTHRITIS AND RHEUMATISM, 63(5), 1200–1210. -
-
Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment
Alten, R., Kaine, J., Keystone, E., Nash, P., Delaet, I., & Genovese, M. C. (2014). Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment. ARTHRITIS & RHEUMATOLOGY, 66(8), 1987–1997. -
A randomized, controlled trial of interferon-beta-1a (Avonex (R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]
Genovese, M. C., Chakravarty, E. F., Krishnan, E., & Moreland, L. W. (2004). A randomized, controlled trial of interferon-beta-1a (Avonex (R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. ARTHRITIS RESEARCH & THERAPY, 6(1), R73–R77. -
Epitope-Specific Immunotherapy of Rheumatoid Arthritis Clinical Responsiveness Occurs With Immune Deviation and Relies on the Expression of a Cluster of Molecules Associated With T Cell Tolerance in a Double-Blind, Placebo-Controlled, Pilot Phase II Trial
Koffeman, E. C., Genovese, M., Amox, D., Keogh, E., Santana, E., Matteson, E. L., … Albani, S. (2009). Epitope-Specific Immunotherapy of Rheumatoid Arthritis Clinical Responsiveness Occurs With Immune Deviation and Relies on the Expression of a Cluster of Molecules Associated With T Cell Tolerance in a Double-Blind, Placebo-Controlled, Pilot Phase II Trial. ARTHRITIS AND RHEUMATISM, 60(11), 3207–3216. -
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis
Hansen, K. E., Hildebrand, J. P., Genovese, M. C., Cush, J. J., Patel, S., Cooley, D. A., … Schiff, M. H. (2004). The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. JOURNAL OF RHEUMATOLOGY, 31(6), 1098–1102. -
-
-
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., CALVO, A., Gomez-Reino, J. J., … Genovese, M. C. (2010). Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. ANNALS OF THE RHEUMATIC DISEASES, 69(1), 88–96. -
-
Demyelination and inhibition of tumor necrosis factor (TNF)
Magnano, M. D., Robinson, W. H., & Genovese, M. C. (2004). Demyelination and inhibition of tumor necrosis factor (TNF). CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 22(5), S134–S140. -
Tocilizumab as Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs: Twenty-Four-Week Results of an Open-Label, Clinical Practice Study
Weinblatt, M. E., Kremer, J., Cush, J., Rigby, W., Teng, L. L., Devenport, J., … Genovese, M. C. (2013). Tocilizumab as Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs: Twenty-Four-Week Results of an Open-Label, Clinical Practice Study. ARTHRITIS CARE & RESEARCH, 65(3), 362–371. -
Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study
Nash, P., Nayiager, S., Genovese, M. C., Kivitz, A. J., Oelke, K., Ludivico, C., … Corbo, M. (2013). Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study. ARTHRITIS CARE & RESEARCH, 65(5), 718–728. -
Longitudinal Evaluation of the Occurrence of MRI-Detectable Bone Marrow Edema in Osteoarthritis of the Knee
Brem, M. H., Schlechtweg, P. M., Bhagwat, J., Genovese, M., Dillingham, M. F., Yoshioka, H., & Lang, P. (2008). Longitudinal Evaluation of the Occurrence of MRI-Detectable Bone Marrow Edema in Osteoarthritis of the Knee. ACTA RADIOLOGICA, 49(9), 1031–1037. -
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Cohen, S. B., Emery, P., Greenwald, M. W., DougadoS, M., Furie, R. A., Genovese, M. C., … Totoritis, M. C. (2006). Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. ARTHRITIS AND RHEUMATISM, 54(9), 2793–2806. -
-
A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Genovese, M. C., Greenwald, M., Cho, C.-S., Berman, A., Jin, L., Cameron, G. S., … Banerjee, S. (2014). A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors. ARTHRITIS & RHEUMATOLOGY, 66(7), 1693–1704. -
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell-Bakalarska, M., Martincova, R., Fiore, S., … van der Heijde, D. (2015). Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis & Rheumatology , 67(6), 1424–37. -
Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
Chakravarty, E. F., Martyanov, V., Fiorentino, D., Wood, T. A., Haddon, D. J., Jarrell, J. A., … Chung, L. (2015). Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Research & Therapy, 17, 159-? -
-
-
Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis
Moreland, L. W., Genovese, M. C., Sato, R., & Singh, A. (2006). Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 55(2), 287–293. -
-
-
-
-
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., … Nirula, A. (2014). Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. NEW ENGLAND JOURNAL OF MEDICINE, 370(24), 2295–2306. -
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients - Patient-reported outcomes from multiple controlled and open-label extension studies
Schiff, M. H., Yu, E. B., Weinblatt, M. E., Moreland, L. W., Genovese, M. C., White, B., … Woolley, J. M. (2006). Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients - Patient-reported outcomes from multiple controlled and open-label extension studies. DRUGS & AGING, 23(2), 167–178. -
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
Kremer, J., Li, Z.-G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., … Bradley, J. (2013). Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial. ANNALS OF INTERNAL MEDICINE, 159(4), 253-? -
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
van Holten, J., Pavelka, K., Vencovsky, J., Stahl, H., Rozman, B., Genovese, M., … Tak, P. P. (2005). A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 64(1), 64–69. -
-
The Early Rheumatoid Arthritis (ERA) Trial comparing the efficacy and safety of etanercept and methotrexate
Bathon, J. M., & Genovese, M. C. (2003). The Early Rheumatoid Arthritis (ERA) Trial comparing the efficacy and safety of etanercept and methotrexate. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 21(5), S195–S197. -
-
-
-
-
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
Genovese, M. C., Hsia, E., Belkowski, S. M., Chien, C., Masterson, T., Thurmond, R. L., … Greenspan, A. (2015). Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. Journal of Rheumatology, 42(10), 1752–60. -
-
-
-
-
-
-
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
Keystone, E. C., Genovese, M. C., Hall, S., Bae, S.-C., Han, C., Gathany, T. A., … Hsia, E. C. (2016). Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. Journal of Rheumatology, 43(2), 298–306. -
Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.
Mease, P. J., Genovese, M. C., Mutebi, A., Viswanathan, H. N., Chau, D., Feng, J., … Nirula, A. (2016). Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. Journal of Rheumatology, 43(2), 343–49. -
-
-
-
-
-
-
Cutting edge: A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues
Pan, J. L., Kunkel, E. J., Gosslar, U., Lazarus, N., Langdon, P., Broadwell, K., … Soler, D. (2000). Cutting edge: A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. JOURNAL OF IMMUNOLOGY, 165(6), 2943–49. -
-
-
-
-
-
-
-
-
-
-
-
-
-
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
Burmester, G. R., Landew, R., Genovese, M. C., Friedman, A. W., Pfeifer, N. D., Varothai, N. A., & Lacerda, A. P. (2017). Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 76(2), 414–17. -
-
-
-
-
-
-
-
-
-
Rituximab in the treatment of patients with dermatomyositis: 12 week interim analysis of a pilot trial.
Chung, L., Genovese, M. C., & Fiorentino, D. (2005). Rituximab in the treatment of patients with dermatomyositis: 12 week interim analysis of a pilot trial. ARTHRITIS AND RHEUMATISM, 52(12), 4088. -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Wordsworth, P., Buchanan, J., Fleischmann, R., Genovese, M., Kay, J., Hsia, E., … Parasuraman, S. (2009). GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. RHEUMATOLOGY. OXFORD UNIV PRESS. -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
Genovese, M. C., Weinblatt, M. E., Mease, P. J., Aelion, J. A., Peloso, P. M., Chen, K., … Leszczynski, P. (2018). Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford, England). -
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
Genovese, M. C., Combe, B., Kremer, J. M., Tsai, T.-F., Behrens, F., Adams, D. H., … Nash, P. (2018). Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford, England). -
-
-
-
-
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin beta Receptor Fusion Protein, in Primary Sjogren's Syndrome Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial
St Clair, E. W., Baer, A. N., Wei, C., Noaiseh, G., Parke, A., Coca, A., … James, J. A. (2018). Clinical Efficacy and Safety of Baminercept, a Lymphotoxin beta Receptor Fusion Protein, in Primary Sjogren's Syndrome Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. ARTHRITIS & RHEUMATOLOGY, 70(9), 1470–80. -
Patients' perceptions of unmet medical need in rheumatoid arthritis
Curtis, J., Genovese, M., Radawski, C., Hauber, B., Nowell, W. B., Hollis, K., … Cardoso, A. (2018). Patients' perceptions of unmet medical need in rheumatoid arthritis. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 27, 56. -
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., … Winthrop, K. L. (2018). Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. The Journal of Rheumatology. -
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Smolen, J. S., Kang, Y. M., Yoo, W.-H., Emery, P., Weinblatt, M. E., Keystone, E. C., … Ghil, J. (2018). Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 70. -
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Burmestert, G. R., Hagino, O., Dong, Q., Stanislav, M., Gomez-Centeno, A., Selmi, C., … Genovese, M. C. (2018). Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA). ARTHRITIS & RHEUMATOLOGY, 70. -
A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis
Chernoff, D., Levine, Y., Peterfy, C., & Genovese, M. C. (2018). A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 70. -
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Genovese, M. C., Smolen, J. S., Takeuchi, T., Rooney, T. P., Dickson, C. L., Yang, X.-Y., … Winthrop, K. (2018). Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis. ARTHRITIS & RHEUMATOLOGY, 70. -
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Kavanaugh, A., Genovese, M. C., Winthrop, K., Creenwald, M., Ponce, L., Sosa, F. E., … Westhovens, R. (2018). Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Genovese, M. C., Colombel, J.-F., Gellett, A. M., Xu, W., & Hardin, D. (2018). Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis. ARTHRITIS & RHEUMATOLOGY. WILEY. -
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Genovese, M. C., Berkowitz, M., Conaghan, P. G., Davy, K., Inman, D., Fisheleva, E., … Tak, P.-P. (2018). A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate. ARTHRITIS & RHEUMATOLOGY, 70. -
Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases
Postolova, A., & Genovese, M. C. (2018). Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases. ARTHRITIS & RHEUMATOLOGY, 70. -
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Fleischmann, R., Genovese, M. C., Cardoso, A., Sun, L., Chen, Y.-F., Walls, C. D., … Curtis, J. R. (2018). Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily. ARTHRITIS & RHEUMATOLOGY, 70. -
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Fleischmann, R., Pangan, A. L., Mysler, E., Bessette, L., Peterfy, C., Durez, P., … Genovese, M. C. (2018). A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate. ARTHRITIS & RHEUMATOLOGY, 70. -
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Pope, J. E., Quebe, A., Zhu, B., Sun, L., Gaich, C. L., de Leonardis, F., … Genovese, M. C. (2018). Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 70. -
Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
Emery, P., Weinblatt, M. E., Smolen, J. S., Keystone, E. C., Genovese, M. C., Vencovsky, J., … Ghil, J. (2018). Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY. WILEY. -
GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
Kivitz, A. J., Mehta, D. P., Matzkies, F., Mozaffarian, A., Kunder, R., Di Paolo, J., … Genovese, M. C. (2018). GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment
Genovese, M. C., van Hoogstraten, H., St John, G., Dong, Q., Jose Gomez-Reino, J., Maldonado-Cocco, J. A., … Burmester, G. R. (2018). Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment. ARTHRITIS & RHEUMATOLOGY, 70. -
-
-
-
-
Inhibition of joint structural damage with rituximab is not dependant on clinical response in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study).
Keystone, E., Emery, P., Peterfy, C. G., Tak, P. P., Cohen, S. B., Genovese, M. C., … Shaw, T. (2006). Inhibition of joint structural damage with rituximab is not dependant on clinical response in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study). ARTHRITIS AND RHEUMATISM, 54(9), S542–S543. -
-
-
-
-
-
-
-
-
-
Signal transduction blockade with imatinib mesylate prevents and treats autoimmune arthritis
Paniagua, R., Sharpe, O., Ho, P., Chan, S., Chang, A., Tomooka, B., … Robinson, W. (2007). Signal transduction blockade with imatinib mesylate prevents and treats autoimmune arthritis. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS. -
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
Kremer, J. M., Schiff, M., Muram, D., Zhong, J., Alam, J., & Genovese, M. C. (2018). Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD Open, 4(1), e000581. -
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.
Kremer, J. M., Genovese, M. C., Keystone, E., Taylor, P. C., Zuckerman, S. H., Ruotolo, G., … Macias, W. L. (2017). Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, N.J.), 69(5), 943–952. -
Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Burmester, G. R., Choy, E., Kivitz, A., Ogata, A., Bao, M., Nomura, A., … Genovese, M. C. (2017). Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(6), 1078–1085. -
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
Smolen, J. S., Kremer, J. M., Gaich, C. L., DeLozier, A. M., Schlichting, D. E., Xie, L., … Combe, B. (2017). Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Annals of the Rheumatic Diseases, 76(4), 694–700. -
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.
Burmester, G. R., Landewé, R., Genovese, M. C., Friedman, A. W., Pfeifer, N. D., Varothai, N. A., & Lacerda, A. P. (2017). Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(2), 414–417. -
VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
Genovese, M. C., van Vollenhoven, R. F., Pacheco-Tena, C., Zhang, Y., & Kinnman, N. (2016). VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, N.J.), 68(1), 46–55. -
Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.
Wilson, H. D., Mutebi, A., Revicki, D. A., Mease, P. J., Genovese, M. C., Erondu, N., … Viswanathan, H. N. (2015). Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis. Arthritis Care & Research, 67(12), 1750–6. -
Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis.
Postolova, A., Troxell, M. L., Wapnir, I. L., & Genovese, M. C. (2019). Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. The Journal of Rheumatology. -
-
-
FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Lee, C., Berman, A., … Genovese, M. C. (2019). FENEBRUTINIB COMPARED TO PLACEBO AND ADALIMUMAB IN PATIENTS WITH INADEQUATE RESPONSE TO EITHER METHOTREXATE THERAPY OR PRIOR TNF THERAPY: PHASE 2 STUDY. ANNALS OF THE RHEUMATIC DISEASES. BMJ PUBLISHING GROUP. -
-
-
-
GS-9876, A NOVEL, HIGHLY SELECTIVE, SYK INHIBITOR IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY
Kivitz, A., Mehta, D., Matzkies, F., Mozaffarian, A., Kunder, R., Di Paolo, J. A., … Genovese, M. C. (2019). GS-9876, A NOVEL, HIGHLY SELECTIVE, SYK INHIBITOR IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY. ANNALS OF THE RHEUMATIC DISEASES. BMJ PUBLISHING GROUP. -
-
-
-
-
TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS)
Dore, R. K., Antonova, J., Burudpakdee, C., Wang, X., Ozbay, B., & Genovese, M. C. (2019). TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS). ANNALS OF THE RHEUMATIC DISEASES. BMJ PUBLISHING GROUP. -
-
-
-
-
-
-
-
-
-
-
-
-
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese, M. C., Kalunian, K., Gottenberg, J.-E., Mozaffarian, N., Bartok, B., Matzkies, F., … Takeuchi, T. (2019). Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA, 322(4), 315–25. -
Long-Term Safety of Ixekizumab in 17034.7 Patient-Years from 15 Global Clinical Trials in Psoriasis and Psoriatic Arthritis: 3-Year Results
Combe, B., Rahman, P., Kameda, H., Canete, J., Gallo, G., Agada, N., … Janos, B. (2019). Long-Term Safety of Ixekizumab in 17034.7 Patient-Years from 15 Global Clinical Trials in Psoriasis and Psoriatic Arthritis: 3-Year Results. JOURNAL OF RHEUMATOLOGY. J RHEUMATOL PUBL CO. -
-
-
-
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Fleischmann, R. M., Genovese, M. C., Enejosa, J. V., Mysler, E., Bessette, L., Peterfy, C., … Song, I.-H. H. (2019). Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Annals of the Rheumatic Diseases. -
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA.
Radawski, C., Genovese, M. C., Hauber, B., Nowell, W. B., Hollis, K., Gaich, C. L., … Curtis, J. R. (2019). Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. Rheumatology and Therapy. -
ASSESSMENT OF PAIN IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB, WHO WERE INADEQUATE RESPONDERS TO METHOTREXATE AND TUMOR NECROSIS FACTOR INHIBITORS
Taylor, P. C., Fleischmann, R., Takeuchi, T., Pope, J., Genovese, M. C., Zhu, B., … Durez, P. (2019). ASSESSMENT OF PAIN IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB, WHO WERE INADEQUATE RESPONDERS TO METHOTREXATE AND TUMOR NECROSIS FACTOR INHIBITORS. RHEUMATOLOGY, 58, 72. -
SAFETY AND EFFICACY OF FILGOTINIB IN A PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
Walker, D., Genovese, M. C., Kalunian, K., Gottenberg, J.-E., de Vlam, K., Mozaffarian, N., … Takeuchi, T. (2019). SAFETY AND EFFICACY OF FILGOTINIB IN A PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS. RHEUMATOLOGY, 58. -
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Genovese, M. C., Greenwald, M. W., Gutierrez-Urena, S. R., Cardiel, M. H., Poiley, J. E., Zubrzycka-Sienkiewicz, A., … Kivitz, A. J. (2019). Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. Rheumatology and Therapy. -
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Peterfy, C., DiCarlo, J., Emery, P., Genovese, M. C., Keystone, E. C., Taylor, P. C., … Macias, W. (2019). MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 46(8), 887–95. -
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Genovese, M. C., van der Heijde, D., Lin, Y., St John, G., Wang, S., van Hoogstraten, H., … Burmester, G. R. (2019). Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open, 5(2), e000887. -
Unique Sjogren's syndrome patient subsets defined by molecular features.
James, J. A., Guthridge, J. M., Chen, H., Lu, R., Bourn, R. L., Bean, K., … St Clair, E. W. (2019). Unique Sjogren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford, England). -
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester, G. R., Strand, V., Rubbert-Roth, A., Amital, H., Raskina, T., Gomez-Centeno, A., … Genovese, M. C. (2019). Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open, 5(2), e001017. -
TNF-alpha inhibition for the treatment of cardiac sarcoidosis.
Baker, M. C., Sheth, K., Witteles, R., Genovese, M. C., Shoor, S., & Simard, J. F. (2019). TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Seminars in Arthritis and Rheumatism. -
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
Genovese, M. C., Glover, J., Greenwald, M., Porawska, W., El Khouri, E. C., Dokoupilova, E., … Alten, R. (2019). FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Research & Therapy, 21(1), 281. -
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.
Smolen, J. S., Choe, J.-Y. Y., Weinblatt, M. E., Emery, P., Keystone, E., Genovese, M. C., … Ghil, J. (2020). Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open, 6(1). -
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
Combe, B., Rahman, P., Kameda, H., Canete, J. D., Gallo, G., Agada, N., … Genovese, M. C. (2020). Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Research & Therapy, 22(1), 14. -
SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 6 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS
Genovese, M., Smolen, J., Takeuchi, T., Rooney, T., Dickson, C., Yang, X.-Y., … Gomez, D. (2019). SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 6 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 25, S49–S50. -
Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
Genovese, M., Sanchez-Burson, J., Balazs, E., Everding, A., Oh, M. S., Fanjiang, G., & Cohen, S. (2019). Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components. ARTHRITIS & RHEUMATOLOGY, 71. -
Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study
Cohen, S., Tuckwell, K., Kunder, R., Katsumoto, T., Zhao, R., Berman, A., … Genovese, M. (2019). Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
Genovese, M., Sanchez-Burson, J., Balazs, E., Everding, A., Oh, M. S., Fanjiang, G., & Cohen, S. (2019). Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA. ARTHRITIS & RHEUMATOLOGY, 71. -
Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis
Peterfy, C., Genovese, M., Song, I.-H., Friedman, A., Hall, S., Mysler, E., … Strand, V. (2019). Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 71. -
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Genovese, M., de Vlam, K., Gottenberg, J.-E., Bartok, B., Tiamiyu, I., Guo, Y., … Kalunian, K. (2019). A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs. ARTHRITIS & RHEUMATOLOGY, 71. -
Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Genovese, M., Kameda, H., Rahman, P., Canete, J., Garces, S., Xu, W., … Combe, B. (2019). Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Dore, R., Antonova, J., Gorritz, M., Chang, L., He, J., & Genovese, M. (2019). Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US. ARTHRITIS & RHEUMATOLOGY, 71. -
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate-CREDO1 Study
Nasonov, E., Fatenejad, S., Korneva, E., Krechikova, D., Maslyansky, A., Plaksina, T., … Genovese, M. (2019). Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate-CREDO1 Study. ARTHRITIS & RHEUMATOLOGY, 71. -
Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator
Gaylis, N., Sikes, D., Kivitz, A., Horowitz, D., Peterfy, C., Levine, Y., … Genovese, M. (2019). Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator. ARTHRITIS & RHEUMATOLOGY, 71. -
Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Baker, M., Sheth, K., Simard, J., Shoor, S., & Genovese, M. (2019). Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Fleischmann, R., Enejosa, J. J., Song, I.-H., Mysler, E., Bessette, L., Peterfy, C., … Genovese, M. (2019). Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks. ARTHRITIS & RHEUMATOLOGY, 71. -
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Fleischmann, R., Genovese, M., Blanco, R., Hall, S., Thomson, G., Van den Bosch, F., … Song, I.-H. (2019). Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response. ARTHRITIS & RHEUMATOLOGY, 71. -
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Fleischmann, R., Selmi, C., Gonzalez-Gay, M. A., van Hoogstraten, H., Hagino, O., Rajput, T., … Genovese, M. (2019). Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study. ARTHRITIS & RHEUMATOLOGY, 71. -
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Dore, R., Antonova, J., Huang, H., Chang, L., Wang, X., & Genovese, M. (2019). Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Genovese, M., Weinblatt, M., Wu, J., Jia, B., Quebe, A., Sun, L., … Pope, J. (2019). Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Winthrop, K., Genovese, M., Combe, B., Tanaka, Y., Kivitz, A., Matzkies, F., … Burmester, G. (2019). Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 71. -
Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Kavanaugh, A., Westhovens, R., Winthrop, K., Lee, S., Greer, J., DeZure, A., … Genovese, M. (2019). Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
Genovese, M., Smolen, J., Takeuchi, T., Burmester, G., Brinker, D., Rooney, T., … Winthrop, K. (2019). Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis. ARTHRITIS & RHEUMATOLOGY, 71. -
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Genovese, M., Kalunian, K., Gottenberg, J.-E., Bartok, B., Tan, Y. M., Guo, Y., … Takeuchi, T. (2019). Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs. ARTHRITIS & RHEUMATOLOGY, 71. -
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Kalunian, K., Genovese, M., Gottenberg, J.-E., Bartok, B., Pechonkina, A., Guo, Y., … Takeuchi, T. (2019). A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 71. -
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
van de Laar, M. A. F. J., Pope, J., Lee, Y., Fautrel, B., Ikeda, K., Quebe, A., … Taylor, P. (2019). Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY, 71. -
Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Bessette, L., Dougados, M., Mysler, E., Genovese, M., Kinch, C., Kwok, K., … van Vollenhoven, R. (2019). Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials. ARTHRITIS & RHEUMATOLOGY, 71. -
Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Genovese, M., Combe, B., Hall, S., Rubbert-Roth, A., Zhong, S., Meerwein, S., … Fleischmann, R. (2019). Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks. ARTHRITIS & RHEUMATOLOGY, 71. -
Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Dore, R., Antonova, J., Burudpakdee, C., Chang, L., He, J., & Genovese, M. (2019). Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US. ARTHRITIS & RHEUMATOLOGY, 71. -
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Hsu, B., Visich, J., Genovese, M., Walter, K., An, M., Laberge, R.-M., & Dananberg, J. (2019). Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA. ARTHRITIS & RHEUMATOLOGY, 71. -
Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012-2016 US Medicare Data
Dore, R., Chang, L., Ji, Y., Li, S., Antonova, J., & Genovese, M. (2019). Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012-2016 US Medicare Data. ARTHRITIS & RHEUMATOLOGY, 71. -
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai, M., Winthrop, K., Takeuchi, T., Hsieh, T.-Y., Chen, Y.-M., Smolen, J. S., … Genovese, M. C. (2020). Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open, 6(1). -
The road to rheumatoid arthritis prevention: challenges and opportunities.
Chaichian, Y., Genovese, M. C., & Weisman, M. H. (2020). The road to rheumatoid arthritis prevention: challenges and opportunities. Clinical Rheumatology. -
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
Genovese, M. C., Sanchez-Burson, J., Oh, M. S., Balazs, E., Neal, J., Everding, A., … Cohen, S. (2020). Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis. Arthritis Research & Therapy, 22(1), 60. -
Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).
Cohen, S., Tuckwell, K., Katsumoto, T. R., Zhao, R., Galanter, J., Lee, C., … Genovese, M. C. (2020). Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). Arthritis & Rheumatology (Hoboken, N.J.). -
High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis.
Boyapati, A., Schwartzman, S., Msihid, J., Choy, E., Genovese, M. C., Burmester, G. R., … Graham, N. M. (2020). High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis & Rheumatology (Hoboken, N.J.). -
Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies.
Genovese, M. C., Kellner, H., Arai, Y., Muniz, R., & Alten, R. (2020). Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD Open, 6(1). -
INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Peterfy, C. G., Genovese, M. C., Song, I.-H., Friedman, A., Hall, S., Mysler, E., … Strand, V. (2020). INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 26, 9–10. -
GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING SARILUMAB: RESULTS FROM THE OPEN-LABEL EXTEND STUDY
Fleischmann, R., Selmi, C., Gonzalez-Gay, M. A., van Hoogstraten, H., Hagino, O., Rajput, T., … Genovese, M. C. (2020). GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING SARILUMAB: RESULTS FROM THE OPEN-LABEL EXTEND STUDY. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 26, 80. -
A PHASE 3 CLINICAL PROGRAM OF THREE, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND COIMPARATOR-CONTROLLED STUDIES TO ASSESS THE EFFICACY AND SAFETY OF OTILIMAB IN RA: STUDY DESIGN AND METHODOLOGY
Genovese, M., Taylor, P. C., Boers, M., Strand, V., Saurigny, D., Davy, K., … Fleischmann, R. (2020). A PHASE 3 CLINICAL PROGRAM OF THREE, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND COIMPARATOR-CONTROLLED STUDIES TO ASSESS THE EFFICACY AND SAFETY OF OTILIMAB IN RA: STUDY DESIGN AND METHODOLOGY. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS SWITCHING BETWEEN JAK1-SELECTIVE INHIBITOR UPADACITINIB AND ADALIMUMAB FOLLOWING INSUFFICIENT RESPONSE
Fleischmann, R., Genovese, M. C., Blanco, R., Hall, S., Thomson, G. T. D., Van den Bosch, F., … Song, I.-H. (2020). CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS SWITCHING BETWEEN JAK1-SELECTIVE INHIBITOR UPADACITINIB AND ADALIMUMAB FOLLOWING INSUFFICIENT RESPONSE. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 26, 68. -
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese, M. C., Mysler, E., Tomita, T., Papp, K. A., Salvarani, C., Schwartzman, S., … Lebwohl, M. G. (2020). Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford, England). -
POOLED SAFETY ANALYSES FROM PHASE 3 STUDIES OF FILGOTINIB IN PATIENTS WITH RA
Walker, D., Winthrop, K., Genovese, M. C., Combe, B. G., Tanaka, Y., Kivitiz, A., … Burmester, G. R. (2020). POOLED SAFETY ANALYSES FROM PHASE 3 STUDIES OF FILGOTINIB IN PATIENTS WITH RA. RHEUMATOLOGY, 59. -
INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH MTX IN PATRIENTS WITH RA: ONE-YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAMME
Peterfy, C., Genovese, M. C., Song, I.-H., Friedman, A., Hall, S., Mysler, E., … Strand, V. (2020). INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH MTX IN PATRIENTS WITH RA: ONE-YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAMME. RHEUMATOLOGY, 59. -
GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING SARILUMAB: RESULTS FROM THE OPEN LABEL EXTEND STUDY
Fleischmann, R., Selmi, C., Angel Gonzalez-Gay, M., van Hoogstraten, H., Hagino, O., Rajput, T., … Genovese, M. C. (2020). GLUCOCORTICOID DOSE IS PROGRESSIVELY REDUCED IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING SARILUMAB: RESULTS FROM THE OPEN LABEL EXTEND STUDY. RHEUMATOLOGY, 59, 108. -
EFFECTS OF FILGOTINIB ON ANAEMIA, THROMBOCYTOPOENIA AND LEUKOPOENIA: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RA AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BDMARDS
Walker, D., Genovese, M. C., Kalunian, K., Gottenberg, J.-E., Bartok, B., Tan, Y. M., … Takeuchi, T. (2020). EFFECTS OF FILGOTINIB ON ANAEMIA, THROMBOCYTOPOENIA AND LEUKOPOENIA: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RA AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BDMARDS. RHEUMATOLOGY, 59, 99–100. -
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
Genovese, M. C., Fleischmann, R., Kivitz, A., Lee, E.-B., van Hoogstraten, H., Kimura, T., … Burmester, G. R. (2020). Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Research & Therapy, 22(1), 139. -
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis
Genovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G., Brinker, D., Rooney, T. P., … Winthrop, K. L. (2020). Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. LANCET RHEUMATOLOGY, 2(6), E347–E357. -
SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS
Hall, S., Genovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G., Brinker, D., … Winthrop, K. L. (2020). SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. INTERNAL MEDICINE JOURNAL, 50, 16. -
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Winthrop, K. L., Harigai, M., Genovese, M. C., Lindsey, S., Takeuchi, T., Fleischmann, R., … Dougados, M. (2020). Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. -
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis.
Smolen, J. S., Kang, Y. M., Yoo, W.-H. H., Emery, P., Weinblatt, M. E., Keystone, E. C., … Ghil, J. (2020). Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis Research & Therapy, 22(1), 188. -
Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.
Alten, R., Markland, C., Boyce, M., Kawakami, K., Muniz, R., & Genovese, M. C. (2020). Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases. -
Interleukin-6 receptor blockade or TNFa inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
Genovese, M. C., Burmester, G. R., Hagino, O., Thangavelu, K., Iglesias-Rodriguez, M., John, G. S., … Fleischmann, R. (2020). Interleukin-6 receptor blockade or TNFa inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research & Therapy, 22(1), 206. -
Patient Disease Trajectories in Baricitinib 2-mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Genovese, M., Weinblatt, M., Wu, J., Jia, B., Quebe, A., Sun, L., … Pope, J. (2020). Patient Disease Trajectories in Baricitinib 2-mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs. JOURNAL OF RHEUMATOLOGY. J RHEUMATOL PUBL CO. -
Patient Disease Trajectories in Baricitinib-2mg-treated Patients with Rheumatoid Arthritis and Inadequate Response to csDMARDs
Pope, J., Li, Z., Genovese, M., Otawa, S., Sun, L., Chandran, S., … Dougados, M. (2020). Patient Disease Trajectories in Baricitinib-2mg-treated Patients with Rheumatoid Arthritis and Inadequate Response to csDMARDs. JOURNAL OF RHEUMATOLOGY, 47(7), 1127–28. -
Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study
Genovese, M. C., Gaylis, N. B., Sikes, D., Kivitz, A., Horowitz, D. L., Peterfy, C., … Chernoff, D. (2020). Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. LANCET RHEUMATOLOGY, 2(9), E527–E538. -
Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients With Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Bessette, L., Dougados, M., Mysler, E., Genovese, M., Kinch, C., Kwok, K., … van Vollenhoven, R. (2020). Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients With Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials. JOURNAL OF RHEUMATOLOGY, 47(7), 1106–7. -
Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Keystone, E., Winthrop, K., Genovese, M., Combe, B., Tanaka, Y., Kivitz, A., … Burmester, G. (2020). Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATOLOGY, 47(7), 1108. -
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study
Genovese, M. C., Berkowitz, M., Conaghan, P. G., Peterfy, C., Davy, K., Fisheleva, E., … Tak, P. P. (2020). MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. LANCET RHEUMATOLOGY, 2(11), E666–E676. -
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study.
Genovese, M., Spindler, A., Sagawa, A., Park, W., Dudek, A., Kivitz, A., … Nirula, A. (2020). Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study. The Journal of Rheumatology. -
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
Cohen, S., Fiechtner, J., Mease, P., Kaine, J., Kavanaugh, A., Cheng, Y.-L. (I., … Genovese, M. (2020). Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study
Marsal, S., Corominas, H., De Agustin De Oro, J. J., Perez Garcia, C., Lopez Lasanta, M., Borrell, H., … Baker, M. (2020). Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study. ARTHRITIS & RHEUMATOLOGY. WILEY. -
A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate
Peterfy, C., Buch, M., Choy, E., Schett, G., Parsons-Rich, D., Patel, A., … Genovese, M. (2020). A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Genovese, M., Lertratanakul, A., Anderson, J. K., Papp, K., Tillett, W., Van den Bosch, F., … Mease, P. (2020). Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks
Fleischmann, R., Song, I.-H., Enejosa, J., Mysler, E., Bessette, L., Durez, P., … Genovese, M. (2020). Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks. ARTHRITIS & RHEUMATOLOGY. WILEY. -
A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Gottenberg, J.-E., Buch, M., Caporali, R., Wright, G., Takeuchi, T., Kalunian, K., … Genovese, M. (2020). A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs. ARTHRITIS & RHEUMATOLOGY. WILEY. -
Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.
Ptacek, J., Hawtin, R. E., Sun, D., Louie, B., Evensen, E., Mittleman, B. B., … Bridges, S. L. (2021). Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. PloS One, 16(1), e0244187. -
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2)
Takeuchi, T., Matsubara, T., Atsumi, T., Amano, K., Ishiguro, N., Sugiyama, E., … Tanaka, Y. (2020). Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). MODERN RHEUMATOLOGY, 1–16. -
Safety and Efficacy of Filgotinib: Up to 4-Year Results From an Open-Label Extension Study of Phase 2 Rheumatoid Arthritis Programs.
Kavanaugh, A., Westhovens, R. R., Winthrop, K. L., Lee, S. J., Tan, Y. M., An, D., … Genovese, M. C. (2021). Safety and Efficacy of Filgotinib: Up to 4-Year Results From an Open-Label Extension Study of Phase 2 Rheumatoid Arthritis Programs. The Journal of Rheumatology. -
Vagus nerve stimulation in rheumatoid arthritis Reply
Genovese, M. C., Levine, Y. A., & Chernoff, D. (2021). Vagus nerve stimulation in rheumatoid arthritis Reply. LANCET RHEUMATOLOGY, 3(1), E14–E15. -
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
Fleischmann, R., Genovese, M. C., Maslova, K., Leher, H., Praestgaard, A., & Burmester, G. R. (2021). Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. Rheumatology (Oxford, England). -
Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study
Marsal, S., Corominas, H., Jose de Agustin, J., Perez-Garcia, C., Lopez-Lasanta, M., Borrell, H., … Baker, M. C. (2021). Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. LANCET RHEUMATOLOGY, 3(4), E262–E269. -
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies.
Genovese, M. C., Durez, P., Fleischmann, R., Tanaka, Y., Furst, D., Yamanaka, H., … Takeuchi, T. (2021). Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. European Journal of Rheumatology. -
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Fraenkel, L., Bathon, J. M., England, B. R., St Clair, E. W., Arayssi, T., Carandang, K., … Akl, E. A. (2021). 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. -
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Fraenkel, L., Bathon, J. M., England, B. R., St Clair, E. W., Arayssi, T., Carandang, K., … Akl, E. A. (2021). 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, N.J.). -
Corrigendum to 'TNF-alpha Inhibition for the Treatment of Cardiac Sarcoidosis' Seminars in Arthritis and Rheumatism. 2020 Jun;50(3):546-552.
Baker, M. C., Sheth, K., Witteles, R., Genovese, M. C., Shoor, S., & Simard, J. F. (2021). Corrigendum to 'TNF-alpha Inhibition for the Treatment of Cardiac Sarcoidosis' Seminars in Arthritis and Rheumatism. 2020 Jun;50(3):546-552. Seminars in Arthritis and Rheumatism. -
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSA AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMISED CONTROLLED PHASE III TRIAL
Genovese, M. C., Lertratanakul, A., Anderson, J., Papp, K., Tillett, W., van den Bosch, F., … Mease, P. (2021). EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSA AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMISED CONTROLLED PHASE III TRIAL. RHEUMATOLOGY. OXFORD UNIV PRESS. -
Targeting GM-CSF in rheumatological conditions: risk of PAP Reply
Genovese, M. C., Buckley, C. D., Saurigny, D., Schett, G., Davy, K., Gupta, A., … Tak, P. P. (2021). Targeting GM-CSF in rheumatological conditions: risk of PAP Reply. LANCET RHEUMATOLOGY, 3(7), E473–E474. -
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
Nasonov, E., Fatenejad, S., Feist, E., Ivanova, M., Korneva, E., Krechikova, D. G., … Genovese, M. (2021). Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Annals of the Rheumatic Diseases. -
Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis
Mease, P., Smolen, J., Kavanaugh, A., Nash, P., Gallo, G., Liu-Leage, S., … Bessette, L. (2021). Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis. JOURNAL OF RHEUMATOLOGY. J RHEUMATOL PUBL CO. -
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese, M. C., Mysler, E., Tomita, T., Papp, K. A., Salvarani, C., Schwartzman, S., … Lebwohl, M. G. (2021). Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford, England). -
The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States.
Dore, R. K., Antonova, J. N., Burudpakdee, C., Chang, L., Gorritz, M., & Genovese, M. C. (2021). The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States. ACR Open Rheumatology. -
Twenty-four-week Follow-up of a Randomized Controlled First-in-Human Trial of the Safety and Efficacy of Neurostimulation with a Miniaturized Vagus Nerve Stimulation Device in Patients with Multidrug-Refractory Rheumatoid Arthritis
Gaylis, N., Genovese, M., Sikes, D., Kivitz, A., Horowitz, D., Peterfy, C., … Chernoff, D. (2021). Twenty-four-week Follow-up of a Randomized Controlled First-in-Human Trial of the Safety and Efficacy of Neurostimulation with a Miniaturized Vagus Nerve Stimulation Device in Patients with Multidrug-Refractory Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY. WILEY. -
A phase 2 randomized controlled trial of the Janus Kinase (JAK) inhibitor filgotinib in patients with noninfectious uveitis
Srivastava, S. K., Watkins, T., Quan Dong Nguyen, Sharma, S., Scales, D., Dacey, M., … Rosenbaum, J. T. (2022). A phase 2 randomized controlled trial of the Janus Kinase (JAK) inhibitor filgotinib in patients with noninfectious uveitis. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. -
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Montalban, X., Wallace, D., Genovese, M. C., Tomic, D., Parsons-Rich, D., Le Bolay, C., … Guehring, H. (2022). Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. Journal of Neurology, Neurosurgery, and Psychiatry. -
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.
Montalban, X., Wallace, D., Genovese, M. C., Tomic, D., Parsons-Rich, D., Bolay, C. L., … Guehring, H. (2023). A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis. Neurodegenerative Disease Management. -
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.
Baker, M. C., Kavanagh, S., Cohen, S., Matsumoto, A. K., Dikranian, A., Tesser, J., … Genovese, M. C. (2023). A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, N.J.). -
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis.
Baker, M. C., Horomanski, A., Wang, Y., Yuhan, L., Parsafar, S., Fairchild, R., … Genovese, M. C. (2023). A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis. Rheumatology (Oxford, England).
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis »
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis »
- A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis »
- Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease »
- Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease »
- Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA) »
- Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee »
- Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis »
Practice Locations
Psoriasis Clinic Redwood City, CA
Redwood City, CAPsoriasis Clinic
450 Broadway Street, Pavilion B, 4th Floor
Redwood City , CA 94063
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(99 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology orders
- View referral status
- Access medical records